Replies to post #183532 on Anavex Life Sciences Corp (AVXL)

[Talon38]

Dr Lisak's preclinical of 2-73:

-------

Oral Presentation Details:
Session: Remyelination: from biology to clinical trials
Title: Sigma 1 receptor agonists as potential protective and reparative therapy in multiple sclerosis
Date: October 27, 2017
Time: 2:52 pm ECT
Location: Hall B, Le Palais des Congrès de Paris
2 Place de la Porte Maillot
75017 Paris, France
“A unique feature of ANAVEX2-73, compared to another sigma-1 receptor agonist we studied, is that ANAVEX2-73 accelerates the maturation of oligodendrocyte precursor cells (OPC) to oligodendrocytes (OL),” said Dr Robert P. Lisak. “This is an important feature since OPCs can replace lost OLs by maturing into new potential myelin-producing cells. In other words, ANAVEX2-73 might promote remyelination. Further data also demonstrates that ANAVEX2-73 provides protection for OL, OPCs, as well as central nervous system neurons in addition to helping repair by increasing OPC proliferation and maturation in tissue culture.“

“These findings provide additional evidence for the neuroprotective and neurorestorative effects of ANAVEX2-73, as well as further validating the mechanism of our target,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.

Let's turn that "might" into a "does" with a P2 run by Dr Lisak and WSU. The Wayne State Multiple Sclerosis Center serves a population of more than 4,000 MS patients with the largest group of African Americans in the country. It is designated by the National Multiple Sclerosis Society as a Center for Comprehensive MS Care and is a member of the Consortium of Multiple Sclerosis Center. It is nationally and internationally recognized for patient care, innovative technology and cutting edge research. We provide high quality care and we work closely with other specialties, including neuropsychologists, urologists, physical, occupational and speech therapists. We see patients with a wide range of autoimmune disorders, including:

Multiple Sclerosis

[nidan7500]

Talon38:

He says that Biogen would like to take the MS cure science and apply it to a wider group of neurodegenerative diseases....that would mean using 2-73's homeostasis properties to treat Alzheimers. And consequently, it would require Biogen to buy the whole 2-73 franchise. It is obvious that any current offer to Anavex in not substantial enough, but with success in any of the three trials, IMHO Biogen will have to significantly up the ante of fold. Then who among the "Big Boys" will call.

------

Previous post discussing this issue:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143735763

Totally agree w/this assessment. The curious thing to me has been what will trigger the (seemingly certain) next steps??? A demonstration as proof by trial of CNS disease efficacy? All the pieces are there now, is it a simple matter of DENIAL?Do they believe the science or not? This is where leadership matters.This is NOT A DRILL.